Carboplatin monotherapy in recurrent uterine leiomyosarcoma with homozygous BRCA2 deletion: a case report

Uterine leiomyosarcoma (ULMS) is a rare gynecological malignancy with a high recurrence rate and poor prognosis. No standard treatment exists for recurrent cases. Recent studies indicate that homozygous BRCA2 deletion may serve as a therapeutic target in non-BRCA-associated malignancies, including ULMS. Here, we report a 49-year-old woman with recurrent BRCA2-deficient ULMS who responded to carboplatin monotherapy. Although PARP inhibitors have been utilized in BRCA-mutated ULMS, this case underscores the potential efficacy of platinum-based chemotherapy as an alternative treatment strategy. Furthermore, a therapeutic approach integrating platinum-based chemotherapy followed by PARP inhibitor maintenance, similar to that employed in platinum-sensitive ovarian cancer, warrants further investigation.